Cargando…

Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma

We compared neutralizing antibody titers of convalescent samples collected before and after the emergence of novel strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), against the wild-type virus and Alpha (B.1.1.7) and Beta (B.1.351) variants. Plasma samples collected in 2020 be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Dung, Xiao, Julie, Simmonds, Peter, Lamikanra, Abigail, Odon, Valerie, Ratcliff, Jeremy, Townsend, Alain, Roberts, David J, Harvala, Heli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689936/ https://www.ncbi.nlm.nih.gov/pubmed/34751775 http://dx.doi.org/10.1093/infdis/jiab563

Ejemplares similares

The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors
por: Nurmi, Visa, et al.
Publicado: (2023)

Comparability of six different immunoassays measuring SARS‐CoV‐2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction
por: Lamikanra, Abigail, et al.
Publicado: (2021)

Convalescent plasma donors show enhanced cross‐reactive neutralizing antibody response to antigenic variants of SARS‐CoV‐2 following immunization
por: Harvala, Heli, et al.
Publicado: (2022)

Detection frequencies and viral load distribution of parvovirus B19 DNA in blood and plasma donations in England
por: Williams, Sarah, et al.
Publicado: (2022)

Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients
por: Muecksch, Frauke, et al.
Publicado: (2020)

Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection
por: Ratcliff, Jeremy, et al.
Publicado: (2021)

Comparison of SARS‐CoV‐2 neutralizing antibody testing of convalescent plasma donations in the Netherlands and England: A pilot study
por: Harvala, Heli, et al.
Publicado: (2021)

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Crawford, Katharine H D, et al.
Publicado: (2020)

Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer
por: Bloch, Evan M, et al.
Publicado: (2021)

Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma
por: Girardin, Roxie C, et al.
Publicado: (2021)

Evaluation of SARS‐CoV‐2 antibody titers and potency for convalescent plasma donation: a brief commentary
por: Wouters, Elise, et al.
Publicado: (2020)

Neutralizing antibodies in convalescent patients
por: Uhl, Lion F. K., et al.
Publicado: (2020)

Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019
por: Bainbridge, Emma D, et al.
Publicado: (2021)

Evidence for Congenital Zika Virus Infection From Neutralizing Antibody Titers in Maternal Sera, Northeastern Brazil
por: Moreira-Soto, Andres, et al.
Publicado: (2017)

A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019
por: Maor, Yasmin, et al.
Publicado: (2023)

Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma
por: Bonny, Tania S, et al.
Publicado: (2020)

Quantity of Vaccine Poliovirus Shed Determines the Titer of the Serum Neutralizing Antibody Response in Indian Children Who Received Oral Vaccine
por: Giri, Sidhartha, et al.
Publicado: (2018)

Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial
por: Fish, M., et al.
Publicado: (2022)

Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2022)

Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020
por: Mehew, Jennifer, et al.
Publicado: (2020)

Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials
por: Shankar-Hari, Manu, et al.
Publicado: (2020)

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J, et al.
Publicado: (2022)

Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial
por: Baksh, Sheriza N, et al.
Publicado: (2023)

Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19–Convalescent Individuals
por: Luczkowiak, Joanna, et al.
Publicado: (2021)

Evaluating the risk of transfusion and transplant‐transmitted monkeypox infections
por: Harvala, Heli, et al.
Publicado: (2022)

Vibriocidal Titer and Protection From Cholera in Children
por: Ritter, Alaina S, et al.
Publicado: (2019)

Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days
por: Haymond, Amanda, et al.
Publicado: (2021)

Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection
por: Miyakawa, Kei, et al.
Publicado: (2021)

Assessment of SARS-CoV-2 neutralizing antibody titers in breastmilk from convalescent and vaccinated mothers
por: Bäuerl, Christine, et al.
Publicado: (2023)

Investigating Blood Donors With Postdonation Respiratory Tract Symptoms During the Wild-Type, Delta, and Omicron Waves of the Coronavirus Disease 2019 Pandemic in England
por: Gates, Shannah, et al.
Publicado: (2023)

Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2
por: Klingler, Jéromine, et al.
Publicado: (2020)

Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials
por: Levine, Adam C, et al.
Publicado: (2023)

Differential Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Response in Inactivated Virus–Vaccinated, Convalescent, and Breakthrough-Infected Subjects
por: Duarte, Luisa F, et al.
Publicado: (2023)

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses
por: Lawrenz, Jan, et al.
Publicado: (2022)

Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults
por: Roa, Camilo C, et al.
Publicado: (2023)

Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy
por: Gontu, Abhinay, et al.
Publicado: (2021)

Changes in the Syphilis Rapid Plasma Reagin Titer Between Diagnosis and Treatment
por: Pandey, Katrina, et al.
Publicado: (2022)

Understanding the outcomes of COVID-19 – does the current model of an acute respiratory infection really fit?
por: Simmonds, Peter, et al.
Publicado: (2020)

Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein
por: Upasani, Vinit, et al.
Publicado: (2023)

Titers of Neutralizing Antibodies against SARS-CoV-2 Are Independent of Symptoms of Non-Severe COVID-19 in Young Adults
por: Jonsdottir, Hulda R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k0vu8o9n7vlrosdqp5ffq02d7e